You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 1
  • 02.01 Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumour necrosis factor inhibitors: A systematic review and meta-analysis

Article Text

Article menu
Download PDFPDF
New players and novel targets in inflammation
02.01 Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumour necrosis factor inhibitors: A systematic review and meta-analysis
  1. Hussien Ahmed1,2,3,
  2. Abdelrahman Ibrahim Abushouk3,4,5,
  3. Ammar Ismail3,5,
  4. Ahmed Elmaraezy3,6,
  5. Ahmed Said Badr3,6,7,
  6. Mohamed Gadelkarim3,9,
  7. Mohammed Elnenny3,6
  1. 1Faculty of Medicine, Zagazig University, El Sharkia, Egypt
  2. 2Student Research Unit, Zagazig University, El Sharkia, Egypt
  3. 3Medical Research Group of Egypt, Cairo, Egypt
  4. 4Faculty of Medicine, Ain shams University, Cairo, Egypt
  5. 5NovaMed Medical Research Association, Cairo, Egypt
  6. 6Faculty of Medicine, Al Azhar University, Cairo, Egypt
  7. 7Faculty of Medicine, Menoufia University, Menoufia, Egypt
  8. 8Student Research Unit, Menoufia University, Menoufia, Egypt
  9. 9Faculty of Medicine, Alexandria University, Alexandria, Egypt

Abstract

Background We conducted this systematic reviews and meta-analysis to investigate the safety and efficacy of ocrelizumab in patients with active rheumatoid arthritis (RA) who exhibited resistance or intolerance to methotrexate or TNF inhibitors.

Materials and methods We performed a web-based literature search of PubMed, Google Scholar, EBSCO, Scopus, Embase, and Web of science for studies that compared ocrelizumab plus methotrexate versus methotrexate plus placebo in RA patients. Data were extracted from eligible studies and pooled as risk ratios (RR), using RevMan software.

Results Pooling data from four RCTs (2230 patients) showed that ocrelizumab plus methotrexate were superior to methotrexate plus placebo at 24 weeks in terms of the American college of rheumatology (ACR20, ACR50, and ACR70) improvement criteria (p<0.00001), disease activity score 28-ESR (RR=3.77, 95% CI [2.47, 5.74], p<0.00001), and Sharp/van der Heijde radiological improvement score (RR=1.63, 95% CI [1.43, 1.85], p<0.00001). These effects were consistent among all ocrelizumab doses. The rates of serious adverse events were comparable between the ocrelizumab and placebo containing groups (RR=1, 95% CI [0.78, 1.28], p=0.98). However, infusion related reactions were significantly higher in ocrelizumab group (RR=2.13, 95% CI [1.69, 2.68], p<0.00001), compared to placebo group.

Conclusion The combination of ocrelizumab plus methotrexate was superior to methotrexate plus placebo on all clinical and radiographic improvement scales. The incidence of adverse events, including serious adverse events, was comparable between both groups. Future trials should investigate the efficacy of ocrelizumab alone and develop strategies to alleviate its related infusion reactions.

https://doi.org/10.1136/annrheumdis-2016-211050.1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.